Russia has authorised the one-shot Sputnik Light version of its Covid-19 vaccine for use, the Russian Direct Investment Fund (RDIF) said on Thursday, a move that could help vaccine supplies go further in countries with high infection rates.
Developed by Moscow's Gamaleya Institute, the slimmed-down vaccine, which the RDIF said is 79.4 per cent effective against Covid-19 and costs under $10 a dose, has been earmarked for export and could increase the number of people with partial immunity.
One of its main potential uses is as a vaccine that can be shipped to a country in the grip of an acute outbreak which needs to be subdued quickly.
"The single-dose Sputnik Light vaccine demonstrated 79.4 percent efficacy according to analysed data taken from 28 days after the injection was administered as part of Russia's mass vaccination programme between 5 December 2020 and 15 April 2021," the RDIF said in a statement.
A Phase III clinical trial involving 7,000 people was under way in Russia, the United Arab Emirates, Ghana and other countries, the RDIF said. Interim results are expected later this month.